

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

NANO:002USD1

10/072,320

List of Patents and Publications for Applicant's

Applicant

Russell Mumper and Michael Jay

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

February 7, 2002

1615

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A3	3,922,260	11/25/75	Peniston et al.	260	211	08/24/73
	A4	5,102,666	04-1992	Acharya	424	487	
	A5	5,362,737	11/1994	Vora et al.	514	291	
	A6	5,446,070 A	08-1995	Mantelle, Juan A.	514	772.6	
	A7	5,639,469	06-1997	Benes et al.	424	435	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Bechgaard et al., "Solubilization of various benzodiazepines for intranasal administration, a pilot study," <i>Pharm Dev Tech</i> , 2:293-296, 1997.
	C2	Binnie et al., "Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers," <i>Compend Contin Educ Dent</i> , 18:1116-1118, 1997.
	C3	Casetta and Negretti, "Salivary immune responses after gingival immunization with tetravaccinal and bivalent formulations of inactivated micro-organisms," <i>Dev Biol Stand</i> , 92:317-321, 1998.
	C4	Chang, "Stability of hirudin, a thrombin-specific inhibitor," <i>J Biol Chem</i> , 266:10839-10843, 1991.
	C5	Eric and Caroline, "Influence of storage conditions on the activity of recombinant hirudin," <i>Thromb Res</i> , 61:87-89, 1991.
	C6	Eriksson et al., "Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement," <i>J Bone Joint Surg Am</i> , 79:326-333, 1997.


2557/817.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Not
considered

2/06

Does
not
comply
with
1.97(c)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

NANO:002USD1

10/072,320

List of Patents and Publications for Applicant's

Applicant

Russell Mumper and Michael Jay

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

February 7, 2002

1615

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	Esslinger <i>et al.</i> , "Pharmacodynamic and safety results of PEG-hirudin in healthy volunteers," <i>Throm Haemost</i> , 77:911-919, 1997.
	C8	Etchart <i>et al.</i> , "Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus hemagglutinin," <i>J Gen Virol</i> , 78:1577-1580, 1997.
	C9	Fenton <i>et al.</i> , "Thrombin inhibition by hirudin: how hirudin inhibits thrombin," <i>Haemostasis</i> , 21:27-31, 1991.
	C10	Fenton, "Thrombin interactions with hirudin," <i>Sem Thromb Hemost</i> , 15:265-268, 1989.
	C11	Garcia-Closas <i>et al.</i> , "Epidemiologic determinants of vaginal pH," <i>Am J Obstet Gynecol</i> , 180:1060-1066, 1999.
	C12	Heath <i>et al.</i> , "Mechanism of triclosan inhibition of bacterial fatty acid synthesis," <i>J Biol Chem</i> , 274:11110-11114, 1999.
	C13	Hjortkjaer <i>et al.</i> , "Single- and repeated-dose local toxicity in the nasal cavity of rabbits after intranasal administration of different glycols for formulations containing benzodiazepines," <i>J Pharm Pharmacol</i> , 51:377-383, 1999.
	C14	Jones <i>et al.</i> , "Targeting and delivery of bactericide to adsorbed oral bacteria by use of proteoliposomes," <i>Biochim Biophys Acta</i> , 1147:251-261, 1993.
	C15	Khandwala <i>et al.</i> , "5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: I. clinical demonstration of acceleration of healing and resolution of pain," <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i> , 83:222-230, 1997a.
	C16	Khandwala <i>et al.</i> , "5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: II. Pharmacokinetics and demonstration of clinical safety," <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i> , 83:231-238, 1997b.
	C17	Leopold and Eikeler, "Eudragit E as a coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD)," <i>J Drug Targeting</i> , 6:85-94, 1998.
	C18	Leung <i>et al.</i> , "Mucoadhesive dosage forms for peptide and protein drug delivery," In: <i>Peptide and Protein Drug Delivery</i> , V.H.L. Lee ed. Marcel Dekker, Inc. New York, pp. 741-767, 1991.
	C19	Liu <i>et al.</i> , "DNA vaccines: A new era in vaccinology," <i>Ann NY Acad Sci, New York, NY</i> , 772. 1995.
	C20	Lofsson <i>et al.</i> , "Effect of cyclodextrins and polymers on triclosan availability and substantivity in toothpastes in vivo," <i>J Pharm Sci</i> , 88:1254-1258, 1999.


25577817/1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Not
Considered
1/26/06

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

NANO:002USD1

Serial No.

10/072,320

Applicant

Russell Mumper and Michael Jay

Filing Date:

February 7, 2002

Group:

1615

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C21	Mandel, "Antimicrobial mouthrinses: overview and update," <i>J Am Dent Assoc</i> , 125:2S-10S, 1994.
	C22	March and Nakamura, "Evaluation of the duration of effect of a bioadhesive vaginal moisturizing gel on vaginal pH," 7 th International Congress on the Menopause, Replens Symposium, Stockholm, Sweden, June 20-22, 1993.
	C23	Markwardt, "Development of hirudin as an antithrombotic agent," <i>Sem THromb Hemost</i> , 15:269-282, 1989.
	C24	Markwardt, "Past, present and future of hirudin," <i>Haemostatis</i> , 21:11-26, 1991b.
	C25	Markwart, "Hirudin and derivatives as anticoagulant agents," <i>Thromb Haemost</i> , 66:141-152, 1991a.
	C26	Martin <i>et al.</i> , <i>Martin's Physical Pharmacy: Physical chemical principles in the pharmaceutical sciences</i> , Lea & Febiger, Third Ed., Philadelphia, 1983.
	C27	McGhee and Kiyono, "Mucosal immunity to vaccines: Current concepts for vaccine development and immune response analysis," In: <i>J.E. Ciarri (ed.) Genetically engineered vaccines</i> , Plenum Press, New York, NY, pp. 3-12, 1992a.
	C28	Park and Robinson, "Physico-chemical properties of water insoluble polymers important to mucin/epithelial adhesion," <i>J Cont Rel</i> , 2:47-57, 1985.
	C29	Rathbone <i>et al.</i> , In: <i>Oral J Mucosal Drug Delivery</i> , M.J. Rathbone Ed., Marcel Dekker Inc., New York, 1996.
	C30	<i>Remington's Pharmaceutical Sciences</i> , 18 th Ed., A.R. Gennard, ed. Mack Publishing Company, Easton, PA, 1990.
	C31	Riehl-Bellon <i>et al.</i> , "Purification and biochemical characterization of recombinant hirudin produced by <i>Saccharomyces cerevisiae</i> ," <i>Biochemistry</i> , 28:2941-2949, 1989.
	C32	Robinson and Torres, "C.A.T. DNA Vaccines," <i>Sem Immun</i> , 9:271-283, 1997.
	C33	Saijo <i>et al.</i> , "Inhibition by amoxanox (AA-673) of the immunologically, leukotriene D4- or platelet-activating factor-stimulated bronchoconstriction in guinea pigs and rats," <i>Int Arch Allergy Appl Immunol</i> , 77:315-321, 1985.
	C34	Saijo <i>et al.</i> , "The antiallergic agent amoxanox suppresses SRS-A generation by inhibiting lipoxigenase," <i>Int Arch Allergy Appl Immunol</i> , 79:231-237, 1986.

25577817.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Not
considered1/22
2/06

Form PTO-1449 (modified)

List of Patents and Publications of Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

NANO:002USD1

Serial No.

10/072,320

Applicant

Russell Mumper and Michael Jay

Filing Date:

February 7, 2002

Group:

1615

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C35	Schwagmeier <i>et al.</i> , "Midazolam pharmacokinetics following intravenous and buccal administration," <i>Br J Clin Pharmacol</i> , 46:203-206, 1998.
	C36	Spannagl <i>et al.</i> , "A fast photometric assay for the determination of hirudin," <i>Haemostasis</i> , 21:36-40, 1991.
	C37	Stevens-Simon <i>et al.</i> , "Racial variation in vaginal pH among healthy sexually active adolescents," <i>Sex Transm Dis</i> , 21:168-172, 1994.
	C38	Tang <i>et al.</i> , "Genetic immunization is a simple method for eliciting an immune response," <i>Nature</i> , 356:152-154, 1992.
	C39	Taubes, "Salvation in a snippet of DNA," <i>Science</i> , 278:1711-1714, 1997.
	C40	Ulmer <i>et al.</i> , "Toward the development of DNA vaccines," <i>Curr Opin Immun</i> , 8:531-536, 1996a.
	C41	Urisu <i>et al.</i> , "Inhibitory action amlexanox on interleukin-3-induced enhancement of histamine releasability of human leukocytes," <i>Arerugi</i> , 39(10):1448-1454, 1990. (ABSTRACT)
	C42	Yankauckas <i>et al.</i> , "Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene," <i>DNA Cell Biol</i> , 12:771-776, 1993.
	C43	Zuckerbraun <i>et al.</i> , "Triclosan: cytotoxicity, mode of action, and induction of apoptosis in human gingival cells in vitro," <i>Eur J Oral Sci</i> , 106:628-636, 1998.
	C44	Co-pending U.S. Application No. 09/748,133 filed on December 27, 2000, (NANO:002US).

25577817.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Not
considered

R

2/08

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

NANO:002USD1

10/072,320

List of Patents and Publications for Applicant's

Applicant

Russell Mumper and Michael Jay

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

February 7, 2002

Group:

1618

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A4	5,252,318	10/12/93	Joshi <i>et al.</i>	424	78.04	06/15/90
	A5	5,346,701	09/13/94	Heiber <i>et al.</i>	424	435	02/22/93
	A6	5,441,732	08/15/95	Hoeg <i>et al.</i>	424	78.04	03/18/92
	A7	5,472,704	12/05/95	Santus <i>et al.</i>	424	435	12/27/93
	A8	5,639,469	06/17/97	Benes <i>et al.</i>	424	435	06/15/94
	A9	5,688,520	11/18/97	Karsenty <i>et al.</i>	424	434	05/24/95
	A10	5,780,045	07/14/98	McQuinn <i>et al.</i>	424	434	11/08/96
	A11	5,900,247	05/04/99	Rault <i>et al.</i>	424	434	12/27/96
	A12	5,989,535	11/23/99	Nayak	424	78.02	08/15/97
	A13	5,993,846	11/30/99	Friedman <i>et al.</i>	424	434	04/21/98
	A14	6,004,546	12/21/99	Sachetto	424	78.01	05/14/99
	A15	6,086,911	07/11/00	Godbey	424	448	06/16/98
	A16	6,159,498	12/12/00	Tapolsky <i>et al.</i>	424	449	09/01/98
	A17	6,210,699	04/03/01	Acharya <i>et al.</i>	424	435	04/01/99
	A18	6,319,510	11/20/01	Yates	424	404	02/22/00

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B5	WO 00/54733	03/03/00	WIPO			German

25669841.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Not
Considered
Does
not
comply
w
1.97(c)

Form PTO-1449 (modified)

JUN 28 2006

Atty. Docket No.

NANO:002USD1

Serial No.

10/072,320

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Russell Mumper and Michael Jay

Filing Date:

February 7, 2002

Group:

1618

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C44	Leopold and Eikeler, "Eudragit E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD)," <i>J Drug Target</i> , 6(2):85-94, 1998.
	C45	Nakamura <i>et al.</i> , "Uptake and release of budesonide from mucoadhesive, pH-sensitive copolymers and their application to nasal delivery," <i>J Control Release</i> , 61(3):329-35, 1999.
	C46	Park and Robinson, "Mechanisms of mucoadhesion of poly(acrylic acid) hydrogels," <i>Pharm Res</i> , 4(6):457-64, 1987.
	C47	Ramkissoon-Ganorkar <i>et al.</i> , "Effect of molecular weight and polydispersity on kinetics of dissolution and release from pH/temperature-sensitive polymers," <i>J Biomater Sci Polym Ed</i> 10(10):1149-61, 1999.
	C48	Ryu <i>et al.</i> , "Increased bioavailability of propranolol in rats by retaining thermally gelling liquid suppositories in the rectum," <i>J Control Release</i> , 59(2):163-72, 1999.

25669841.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Filed 12/08/2006

Form PTO-1449 (modified) List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Atty. Docket No. NANO:002USD1	Serial No. 10/072,320
		Applicant Russell Mumper Michael Jay	
		Filing Date: February 7, 2002	Group: 1618
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A19	4,552,751	12/12/85	Inaba <i>et al.</i>	424	449	10/19/81
	A20	4,900,554	02/13/90	Yanagibashi <i>et al.</i>	424	448	12/23/87
	A21	5,081,157	02/14/92	Pomerantz	514	781	02/06/91
	A22	5,081,158	01/14/92	Pomerantz	514	781	03/08/90
	A23	5,192,802	03/09/93	Rencher	514	535	09/25/91
	A24	5,298,258	03/29/94	Akemi <i>et al.</i>	424	484	06/16/92
	A25	5,314,915	05/24/94	Rencher	514	535	12/16/92
	A26	5,800,832	09/01/98	Tapolsky <i>et al.</i>	424	449	10/18/96
	A27	5,955,097	09/21/99	Tapolsky <i>et al.</i>	424	434	10/18/96

Not considered
 Not in compliance w
 1.97(c)

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25689048.1

EXAMINER:	DATE CONSIDERED:
------------------	-------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Filed 2/27/2007

Page 1 of 1

Form PTO-1449 (modified)		Atty. Docket No.: NANO:002USD1	Serial No.: 10/072,320
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Russell Mumper Michael Jay	
		Filing Date: February 7, 2002	Group: 1618
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B6	AU754490 B2	10/18/99	Australia	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25749917.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Not
considered

Does
not
comply
w/
1.97(c)